Physician profile
Nathaniel Avila
NPI 1346683323
$1,454.72
in general payments reported to CMS, 2019-2025
18 companies · $66.26 in 2025
The $66.26 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $162 · 2021: $20.83 · 2022: $745 · 2023: $33.49 · 2024: $138 · 2025: $66.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $325.41 | 2019-2022 | |
| Madrigal Pharmaceuticals | $174.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Astrazeneca Pharmaceuticals LP | $165.01 | 2019-2022 | |
| Abbott Laboratories | $162.41 | 2020 | |
| Sanofi-Aventis U.S. LLC | $111.24 | 2022 | |
| Erbe USA INC | $90.00 | 2019 | |
| Abbvie INC. | $57.58 | 2022-2025 | |
| Celgene Corporation | $48.94 | 2022-2023 | Zeposia |
| Janssen Biotech, INC. | $42.80 | 2022 | |
| Daiichi Sankyo INC. | $42.48 | 2021-2022 | |
| Genzyme Corporation | $42.36 | 2022 | |
| Redhill Biopharma INC. | $41.34 | 2022 | |
| Qol Medical, LLC | $37.10 | 2022 | |
| Gilead Sciences, INC. | $34.78 | 2022-2023 | |
| Medtronic, INC. | $24.04 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.87 | 2022 | |
| Olympus America INC. | $18.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Avila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.